Vista Pharmaceuticals Ltd

Vista Pharmaceuticals Management Change

Vista Pharmaceuticals Ltd announced the resignation of Mrs. Barkha Jain as Company Secretary and Compliance Officer, effective September 4, 2026.

Vista Pharmaceuticals Q1 FY27 Results: Net Loss of ₹1 Cr, Loss Narrows

Vista Pharmaceuticals Ltd reported a net loss of ₹1 Cr for Q1 FY27.

Key figure

Net loss ₹1 Cr

Vista Pharmaceuticals Board Meeting Date

Vista Pharmaceuticals has scheduled a board meeting for August 14, 2026. The board will consider the unaudited financial results for the quarter ended June 30, 2026.

Vista Pharmaceuticals Other Announcement

Vista Pharmaceuticals Ltd submitted its quarterly shareholding pattern for the period ending June 30, 2026, in compliance with SEBI Regulation 31(1)(b).

Vista Pharmaceuticals Other Announcement

Vista Pharmaceuticals Limited submitted its Annual Secretarial Compliance Report for the financial year ended March 31, 2026. The report confirms overall regulatory compliance with no material deviations.

Vista Pharmaceuticals Q4 FY26 Results: Net Loss of ₹5.9 Cr, Loss Widens

Vista Pharmaceuticals Ltd reported a net loss of ₹5.9 Cr for Q4 FY26.

Key figure

Net loss ₹5.9 Cr

Vista Pharmaceuticals Financial Results

Vista Pharmaceuticals reported audited financial results for the year ended March 31, 2026. The company also appointed M/s. LMN & Co. as internal auditors.

Vista Pharmaceuticals Board Meeting Date

Vista Pharmaceuticals scheduled a board meeting on May 29, 2026. Directors will review audited financial results and reports for the fiscal year ending March 2026.

Vista Pharmaceuticals Debt & Borrowing

Vista Pharmaceuticals Limited (BSE: 524711) submitted its annual disclosure for FY 2025-26, confirming it does not meet the criteria for a 'Large Corporate' under SEBI norms. The company reported nil incremental borrowing and no penalties for the current block period.